Survival analysis in gastric cancer: A multi-center study among Iranian patients by Talebi, A. et al.
RESEARCH ARTICLE Open Access
Survival analysis in gastric cancer: a multi-
center study among Iranian patients
Atefeh Talebi1, Afsaneh Mohammadnejad2, Abolfazl Akbari1, Mohamad Amin Pourhoseingholi3, Hassan Doosti4,
Bijan Moghimi-Dehkordi5, Shahram Agah1* and Mansour Bahardoust1,6*
Abstract
Background: Gastric cancer (GC) has been considered as the 5th most common type of cancer and the third
leading cause of cancer-associated death worldwide. The aim of this historical cohort study was to evaluate the
survival predictors for all patients with GC using the Cox proportional hazards, extended Cox, and gamma-frailty
models.
Methods: This historical cohort study was performed according to documents of 1695 individuals having GC
referred to three medical centers in Iran from 2001 to 2018. First, most significant prognostic risk factors on survival
were selected, Cox proportional hazards, extended Cox, gamma-frailty models were applied to evaluate the effects
of the risk factors, and then these models were compared with the Akaike information criterion.
Results: The age of patients, body mass index (BMI), tumor size, type of treatment and grade of the tumor
increased the hazard rate (HR) of GC patients in both the Cox and frailty models (P < 0.05). Also, the size of the
tumor and BMI were considered as time-varying variables in the extended Cox model. Moreover, the frailty model
showed that there is at least an unknown factor, genetic or environmental factors, in the model that is not
measured (P < 0.05).
Conclusions: Some prognostic factors, including age, tumor size, the grade of the tumor, type of treatment and
BMI, were regarded as indispensable predictors in patients of GC. Frailty model revealed that there are unknown or
latent factors, genetic and environmental factors, resulting in the biased estimates of the regression coefficients.
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Background
GC is the 5th leading cause of cancer-related death in
spite of its global decrease in incidence and mortality ac-
cording to GLOBOCAN 2018 data [1]. Despite advances
in diagnostic, therapeutic, and screening methods, the
mortality rate has not significantly decreased worldwide.
In the Iranian population, the prevalence of this cancer
is also increasing as it threatens the health of the popu-
lation [2]. The survival rate of GC is rather low and
often the tumor is not diagnosed until an advanced stage
that the cause is related to clinicopathological factors
[3]. Indeed, malignancy is frequently identified by a vari-
able but poor overall prognosis, particularly in the late
clinical stages. The clinicopathological features of GC
patients are very imperative in choosing the right thera-
peutic strategy that can improve patient survival. In
addition, diagnosis and treatment of GC considerably
depend on prognostic factors and variations of survival
over time [4, 5].
Since identifying the prognosis risk factors for GC pa-
tients is extensively important, researchers are interested
in the survival time until the occurrence of an event in
epidemiological and other data [6]. The most reasonable
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condition in Cox regression is the proportional hazard
(CPH) assumption, which is applied in a short-term
follow-up. If the proportional assumption does not hold,
the results from a CPH model are misleading, and alterna-
tive modelling strategies should be carried out [7]. In a
common phenomenon in clinical research, time-varying
covariance occurs when a given covariate changes over
time during the follow-up period that is called an ex-
tended Cox model. Indeed, the main characteristic of data
with time-dependent covariates is the survivor function
for any individual depending on time and the baseline
hazard function [8]. The frailty model, the random com-
ponent, has been designed to account for variability, and it
has been used when there is at least one unaccounted pre-
dictor in the model [9]. This model assumes that events
(e.g., death) happen earlier for individuals who are more
frailty. Some factors, including hereditary, genetic charac-
teristics, growth, and living environment, are effective in
the caused differences among the patients. When the as-
sumption of proportionality does not hold, applying the
CPH regression leads to a biased estimation and under-
estimation of variance of the parameters [10].
Other studies have been done on survival analysis such
as parametric, artificial neural network, Bayesian and
parametric, multi-state, and Cure models in GC [11–13].
Viduz et al. surveyed the frailty multi-state model on ad-
vanced GC data from the Agamenon National Cancer
Registry [14]. Lu et al. performed Cox regression model
and log-rank test in patients older than 80 years who
underwent radical gastrectomy for primary GC from
2000 to 2012 [15]. Ghadimi et al. analysed the survival
rate of the gastrointestinal patients by parametric models
such as log-normal, log-logistic, Weibull, and exponen-
tial model using with and without frailty, then Akaike in-
formation criterion (AIC) was regarded to evaluate the
models [16]. Faradmal et al. applied Cox and Frailty
models in Breast cancer data and then compared them
with the Concordance index [13].
To the best of our knowledge, this is the first multi-
center study that investigates the main prognostic fac-
tors of GC in Iranian through applying several survival
analysis models. The multi-center study is designed to
survey multiple cities in Iran. The sample size (n = 1695)
is large enough to detect a wide range of associations
with adequate statistical power.
We aimed to evaluate the effect of important variables
on the survival rate of GC patients who registered at
three centers in Iran during 2001–2018, using Cox re-
gression and two semi-parametric models.
Methods
Patient characteristics
In this study, we included 1695 patients who were diag-
nosed to have GC and were registered to three separated
medical centers in Iran, Rasoul Akram hospital (2013–
2018), Taleghani hospital (2003–2007), and Fars prov-
ince in southern Iran (2001–2006) during 2001–2018.
The project was approved in Ethic Committee of Iran
University of Medical Sciences (ethical code: IR.IUMS.-
REC. 1397.481).
 The right-censored data at Rasoul Akram hospital of
Tehran represented a historical cohort of 346 GC
patients, who registered from September 2013 to
November 2018. Demographic and clinical charac-
teristics of patients were obtained by checklists of
patient’s records.
 The right-censored data of Taleghani hospital re-
vealed a retrospective review of 746 GC patients
who enrolled in the study from February 2003 until
January 2007. The patient’s information was gath-
ered by checklists of patient’s records [17].
 The data of the cancer registry of Fars province
center demonstrated a historical cohort study of 603
GC patients from March 2001 to March 2006.
Prognostic factors of GC and patients’ vital status
were collected in March 2006 [18].
The outcome variable was considered as time
(months) elapsed since the cancer diagnosis until death.
Some important clinical variables containing tumor size,
number of involved lymph nodes, distant metastasis,
histology, type of treatment, and demographic variables
such as age, gender, marital status, education, BMI, and
smoking situation were included in the aforementioned
models.
Statistical analysis
Kaplan-Meier, named as the product limit estimator,
was used to estimate survival function. In the first step,
the Univariate CPH model was performed to find the
important factors of GC, chosen variables with P < 0.2 in
the Univariate analysis were subjected to multivariable
regression analysis with P < 0.05. The Cox model is a
very useful approach to survival analysis. On the other
hand, when the assumption of proportionality does not
satisfy, the outputs might be misleading, and then other
different models should be used [7]. In the time-varying
variables, the effects of some predictors depend on the
time that is called time-dependent variables, an extended
version of the CPH model [19]. The proportional hazard
(PH) assumption was assessed using Schoenfeld resid-
uals, and then an extended CPH model was fitted to the
data [7]. Since several substantial factors such as genetic
or environmental factors were not reported in these
data, there was evidence of unmeasured heterogeneity
among the patients, so a frailty model was applied [20].
In the frailty model, an unobserved multiplicative effect
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was considered on hazard function by presuming a g(α)
distribution with the unit mean and unknown variance
of θ. In the third step, gamma distribution was per-
formed as a frailty component in the Cox model [10].
Finally, the evaluation of models was performed based
on the AIC. The significance level for the statistical test
was 0.05. The Stata-13 and R-3.2.2 were applied for all
statistical analysis.
Results
In this study, medical files of 1695 GC patients were
retrospectively reviewed. 949 (56%) were male, and 746
(44%) were female. The mean age of patients at diagno-
sis was 60.28 ± 12.93, and the follow-up time was
18.79 ± 16.67 months. The overall median survival rate
of 1695 patients was 13.2 months. Eight hundred four
(47.4%) of patients were censored, and 891 (52.6%) of
patients died at the end of follow-up. The characteristics
and pathological features of all the GC patients are
presented in Table 1.
Based on Kaplan–Meier estimates, the 5-year survival
rate was assessed 11.3%, while one-year and three-year
survival rates were 63.5 and 37.5%, respectively (Fig. 1).
The test based on Schoenfeld residuals revealed that
some variables, including the size of the tumor, the
grade of the tumor, and BMI (P < 0.05), were violated
from the PH assumption (Global P = 0.04). The results
of the CPH were provided in Table 2. The table showed
that age, sex, smoking, BMI, type of tumor, involved
lymph node, metastasis, type of treatment, tumor size,
the grade of the tumor are significant in the univariate
Cox model (P < 0.15). Moreover, the output of the multi-
variate Cox model revealed that age, BMI, type of treat-
ment, tumor size, and grade of the tumor are statistically
significant (P < 0.05).
A HR of tumor size categories indicated that T2, T3
(larger sizes) had worse prognoses compare to T1 (small
size) (HR = 1.5; HR = 3.6, P < 0.001). Moreover, the HR
of metastasis was 0.3% more than non-metastasis (HR =
1.3; P < 0.001). In addition, the HR of death in patients

















< 60 397 49.4 390 43.8 787 46.4
> 60 403 50.1 501 56.2 904 53.3
Sex
Male 471 58.6 478 53.6 949 56
Female 333 41.4 413 46.4 746 44
Marital status
Unmarried 50 6.2 51 5.7 101 6
Married 749 93.2 835 93.7 1584 93.5
Education
Illiterate 220 27.4 125 14 345 20.4
Primary 199 24.8 199 22.3 398 23.5
University 58 7.2 88 9.9 146 8.6
Family history
Yes 201 25 263 29.5 464 27.4
No 563 70 576 64.6 1139 67.2
BMI
< 18.5 92 11.4 112 12.6 204 12
18.6–24.9 394 49 453 50.8 847 50
> 25 115 14.3 109 12.2 189 11.2
Smoking status
Yes 326 40.5 431 48.4 757 44.7
No 439 54.6 392 44 831 49
Tumor type
Adenocarcinoma 384 47.8 427 47.9 811 47.8
Lymphoma 73 9.1 44 4.9 117 6.9
Other 93 11.6 59 6.6 152 9
Lymph node
N1 139 17.3 136 15.3 275 16.2
N2 209 26 233 26.2 442 26.1
N3 39 6.1 37 4.2 86 5.1
Metastasis
Yes 168 20.9 401 45 569 33.6
No 451 56.1 403 45.2 854 50.4
Treatment
Surgery 437 54.3 470 52.7 907 53.5
Surgery+ chemotherapy 245 30.5 230 25.8 475 28
Chemotherapy+ radiotherapy 122 15.2 191 21.5 313 18.5
Tumor size
T1 118 14.7 107 12 225 13.3
T2 229 28.5 208 23.3 437 25.8
















T3 94 11.7 156 17.5 250 14.7
Grade
Well 286 35.6 300 33.7 586 34.6
Moderate 194 24.1 311 34.9 505 29.8
Poorly 124 15.4 110 12.3 234 13.8
Undifferentiated 165 20.5 126 14.1 291 17.2
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with N2 (N3) was 40% (27%) times more than those
with N1. Additionally, the HR of treatment type in
surgery plus chemotherapy was 0.21% less than
chemotherapy plus radiotherapy that seems to be sig-
nificant (HR = 0.79, P < 0.05). Based on the Multivari-
ate CPH model, the HR of death of patients with
BMI < 18 (underweight) is 2.45 times more than those
with overweight (HR = 2.45, P < 0.001). Also, the AIC
is − 1620.36 in the CPH model. Table 3 showed the
results in evaluating PH to apply the extended Cox
model and frailty model.
Since the PH assumption was not met for tumor size,
age and BMI, CPH model no longer satisfies the PH as-
sumption and therefore an extended Cox model was
performed. Furthermore, the Global test demonstrated
CPH did not seem to be suitable because of non-
proportional hazards (P = 0.04). The result of the ex-
tended Cox model revealed that the size of the tumor
and BMI are time-varying variables (P < 0.05 and the
AIC is − 1452.07 in this model.
Furthermore, Table 3 indicates the significant variables
in the frailty model, including age, tumor size, the grade
of the tumor, and BMI (P < 0.05). The results showed
that the variance of frailty was significantly greater than
zero (θ = 1.67; P < 0.05). According to our finding, there
were latent factors which affect the hazard of death. The
AIC in the frailty model is − 412.72, which is larger than
− 1620.36 and − 1452.07 in CPH and extended Cox
models. These results of comparing AIC in three models
indicate that the best models are frailty, extended Cox,
and CPH, respectively.
Discussion
Survival analysis have mostly performed using common
statistical methods such as CPH that have shortcomings
[2, 21–23]. However, this is the first multi-center study,
comparing different survival models to identify prognos-
tic risk factors in GC patients of developing countries.
GC is a worldwide cause of cancer death with a low 5-
year survival rate in Iran. A number of factors have been
identified as predictive prognosis factors until now [24–
26]. In the recent study, the CPH, extended Cox, gamma
frailty Cox models were fitted to determine the adjusted
hazard of GC patients who underwent treatments, sur-
gery, chemotherapy, and radiotherapy. The significant
variables in the CPH model were age at diagnosis, BMI,
tumor size, type of treatment and grade of the tumor.
Additionally, time-dependent variables, the size of the
tumor, and BMI with time function g(t) = t were consid-
ered in the extended Cox model. Furthermore, the frailty
model was chosen as the best model and demonstrated
that there are latent factors that affect the hazard of
death. The results revealed that age, tumor size, the
grade of the tumor, type of treatment and BMI have a
direct effect on the hazard of death in GC patients.
The results of CPH and frailty models showed a sig-
nificant relationship between age over 60 years at the
time of surgery and the 5-year survival of patients with
Fig. 1 Kaplan–Meier curve, 5-year survival rate
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GC. Similar to our results, previous studies have re-
ported the relationship between age and the 5-year sur-
vival [24, 26]. The main strength of these investigations
was the large sample size that was consistent in our
study. Whilst a contradictory result of a study indicated
that there is not any relationship between older age and
patient survival, which could be because of differences in
the sample size [25]. A retrospective study revealed how
patients over the age of 70 years differ from younger pa-
tients in postoperative courses with a focus on the fre-
quency of surgical and medical [27].
The findings of our study showed that both sizes of
the tumor and tumor grade in patients at the time of
diagnosis in three models were significantly associated
with patients’ survival. The size of tumor and tumor
grade have been identified as a risk factor for the sur-
vival of GC patients, which are compatible with our
study [24, 26] while the result of Nasseri et al. demon-
strated that there is no relationship between the grade of
tumor and GC [28].
The main result of our study showed a significant rela-
tionship between the survival of GC patients with BMI <
18, which was consistent with the findings of BMI in the
study of Liu et al. [29]. In their study, a 320 cohort study
was conducted to survey the effect of BMI and recreational
physical activity on GC risk. It can be illustrated due to an-
orexia, weakness and poor health status of under-weight
patients, therefore the variable can be regarded as indis-
pensable prognostic factor. In general, studies of BMI and
GC have been restricted. Furthermore, combined surgical
treatment and chemotherapy were related to higher survival
rate that the result was consistent with several previous
studies [30–33]. A meta-analysis was performed to survey
the effect of treatment type on GC [33]. Moreover, combin-
ation therapy surgery as well as chemotherapy was signifi-
cant in some cancers such as Hepatocellular carcinoma
[34]. However, an inconsistent study presented the survival
analysis of GC patients with incomplete data that treatment
type was not significant [4].
The frailty model is performed to explain the ran-
dom variation of the survival function that may exist
due to some unobserved genetic prognostic factors
Table 2 Univariate and multivariate analyses of CPH model for
prognosis in GC patients
Univariate Multivariate
HR P HR P
Age (year)
< 60 Ref -















< 18 1.66 < 0.001 2.45 < 0.001















Yes 1.3 < 0.001
Treatment
Chemotherapy+ radiotherapy Ref -
Surgery+ chemotherapy 0.58 0.001 0.79 0.011
Surgery 0.95 0.58 0.85 0.052
Tumor size
T1 Ref -
T2 1.5 < 0.001 2.43 0.002
T3 3.6 < 0.001 2.77 0.001
Table 2 Univariate and multivariate analyses of CPH model for
prognosis in GC patients (Continued)
Univariate Multivariate
HR P HR P
Grade
Undifferentiated Ref -
Well 0.73 0.004 0.650192
Moderate 0.83 0.088 0.38 < 0.001
Poorly 0.96 0.77 0.68 0.129
Abbreviations: HR: Hazard Ratio, Ref Reference group
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such as genetic and other environmental factors.
These results are consistent with the results of many
studies in this field [16, 35].
Based on the AIC, the frailty model is the best alterna-
tive model for the Cox proportional hazard model. This
issue is consistent with most studies conducted on GC
patients [10, 15, 28].
Strengths and limitations
The main strength of the present investigation was the
multi-center study with a large sample size as well as a
lack of missing in the data. The main limitation of this
study was the short- term follow-up period. Further,
studies with longer follow-up periods may provide more
determining evidence regarding the Survival predictors
in GC patients.
Conclusion
The results of this study indicate that the age > 60 years,
tumor size, the grade of tumor, type of treatment and
BMI < 18 kg/m2 are the main prognostic factors in the
survival rate of GC patients. In fact, they are reducing
the survival rate of GC patients. Also, based on our find-
ings from the frailty model, we might conclude that
employing a more intricate statistical model that regards
the significant role of latent variables on hazard ratio,
including unobserved genetic or environmental factors,
would expand the importance of the more analyses.
Abbreviations
HR: Hazard rate; BMI: Body mass index; GC: Gastric cancer; CPH: Cox
proportional hazards model; PH: Proportional hazards; AIC: Akaike
information criterion
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